688 related articles for article (PubMed ID: 11110676)
1. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Slovak ML; Kopecky KJ; Cassileth PA; Harrington DH; Theil KS; Mohamed A; Paietta E; Willman CL; Head DR; Rowe JM; Forman SJ; Appelbaum FR
Blood; 2000 Dec; 96(13):4075-83. PubMed ID: 11110676
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
[TBL] [Abstract][Full Text] [Related]
4. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
5. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
Grimwade D; Walker H; Oliver F; Wheatley K; Harrison C; Harrison G; Rees J; Hann I; Stevens R; Burnett A; Goldstone A
Blood; 1998 Oct; 92(7):2322-33. PubMed ID: 9746770
[TBL] [Abstract][Full Text] [Related]
6. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
[TBL] [Abstract][Full Text] [Related]
8. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
Chalandon Y; Barnett MJ; Horsman DE; Conneally EA; Nantel SH; Nevill TJ; Nitta J; Shepherd JD; Sutherland HJ; Toze CL; Hogge DE
Biol Blood Marrow Transplant; 2002; 8(8):435-43. PubMed ID: 12234169
[TBL] [Abstract][Full Text] [Related]
9. Varying intensity of postremission therapy in acute myeloid leukemia.
Cassileth PA; Lynch E; Hines JD; Oken MM; Mazza JJ; Bennett JM; McGlave PB; Edelstein M; Harrington DP; O'Connell MJ
Blood; 1992 Apr; 79(8):1924-30. PubMed ID: 1562720
[TBL] [Abstract][Full Text] [Related]
10. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
Cassileth PA; Andersen JW; Bennett JM; Harrington DP; Hines JD; Lazarus HM; Mazza JJ; McGlave PP; O'Connell MJ; Paietta E
Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).
Gorin NC; Labopin M; Fouillard L; Meloni G; Frassoni F; Iriondo A; Brunet Mauri S; Goldstone AH; Harousseau JL; Reiffers J; Esperou-Bourdeau H; Gluckman E
Bone Marrow Transplant; 1996 Jul; 18(1):111-7. PubMed ID: 8832003
[TBL] [Abstract][Full Text] [Related]
12. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Harousseau JL; Cahn JY; Pignon B; Witz F; Milpied N; Delain M; Lioure B; Lamy T; Desablens B; Guilhot F; Caillot D; Abgrall JF; Francois S; Briere J; Guyotat D; Casassus P; Audhuy B; Tellier Z; Hurteloup P; Herve P
Blood; 1997 Oct; 90(8):2978-86. PubMed ID: 9376578
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Schlenk RF; Benner A; Hartmann F; del Valle F; Weber C; Pralle H; Fischer JT; Gunzer U; Pezzutto A; Weber W; Grimminger W; Preiss J; Hensel M; Fröhling S; Döhner K; Haas R; Döhner H;
Leukemia; 2003 Aug; 17(8):1521-8. PubMed ID: 12886238
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Tavernier E; Le QH; Elhamri M; Thomas X
Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
[TBL] [Abstract][Full Text] [Related]
15. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
16. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.
Tallman MS; Dewald GW; Gandham S; Logan BR; Keating A; Lazarus HM; Litzow MR; Mehta J; Pedersen T; Pérez WS; Rowe JM; Wetzler M; Weisdorf DJ
Blood; 2007 Jul; 110(1):409-17. PubMed ID: 17374741
[TBL] [Abstract][Full Text] [Related]
17. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
18. Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
Harousseau JL; Pignon B; Dufour P; Ifrah N; Solary E; Abgrall JF; Milpied N; Desablens B; Guyotat D; Herve P
Leukemia; 1992; 6 Suppl 2():120-3. PubMed ID: 1578912
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
[TBL] [Abstract][Full Text] [Related]
20. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
